Why the study?
Athletes represent a distinctive, young, and healthy population who developed myocarditis after COVID-19 infection or COVID-19 mRNA vaccination, requiring synthesis of data on incidence, diagnosis, prognosis, and return to play.
What is the incidence and prognosis of myocarditis following COVID-19 infection or mRNA vaccination in athletes?
What is the incidence and prognosis of myocarditis following COVID-19 infection or mRNA vaccination in athletes?
The risk of myocarditis from COVID-19 infection and mRNA vaccination in athletes is very low, though true incidence may be higher due to asymptomatic cases.
Myocarditis risk in athletes post-COVID or vaccination remains incompletely defined; Level 4 data leaves open prospective risk stratification and return-to-play protocols.
OBJECTIVE: The purpose of this systematic review is to evaluate the original peer-reviewed studies on athletes who developed myocarditis after coronavirus disease (COVID-19) infection or after COVID-19 mRNA vaccination. Both entities likely have an immunologic component. We discuss elite, professional, college, and adolescent athletes. The athletes are generally young and healthy, representing a distinctive population group that differs from the general population. This review includes diagnosis of myocarditis, incidence, complications, prognosis, and return-to-play guidance for sports medicine clinicians and coaches. DATA SOURCES: We surveyed the PUBMED, Embase, and Web of Science databases for the relevant peer-reviewed articles in the English language published from the onset of the pandemic until April 2023. Included were original observational studies and case series. Excluded were individual case reports and a small series with incomplete data. The resulting search yielded 30 original articles. MAIN RESULTS: Reported myocardial abnormalities in athletes were rare after COVID-19 infection and even less frequent after COVID-19 mRNA vaccination. True incidence, however, may be higher because of under-reporting and frequent asymptomatic presentation. Male gender was prevalent for both manifestations; postvaccination myocarditis occurrence was the highest after the second vaccine dose. Diagnostic and return-to-play algorithms were developed and should be adopted and followed. CONCLUSIONS: The risk of myocarditis from COVID-19 infection and COVID-19 mRNA vaccination is very low. The long-term prognosis and evolution of the observed cardiac magnetic resonance abnormalities are currently unknown. Although inferences can be made from the published data, COVID-19 and postvaccine myocarditis in athletes may represent only a small fraction of the true incidence of those who have been affected worldwide and not evaluated.
No takes yet. Share an insight, caveat, or question.
Mahneva et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: